Evaluation of renal function in patients with psoriasis using immunobiologicals.
The aim of this study was to evaluate renal function in patients with psoriasis using immunobiologicals. A prospective study was conducted with 15 patients with confirmed diagnosis of psoriasis who were starting to use immunobiologicals. The mean age was 41 ± 11 years, with 60% females. The mean time of disease was 11 ± 6.6 years. Significant changes in creatinine and creatinine clearance were not observed in the course of the study. There was an increase in transaminases and a decrease in magnesium levels.
Fortaleza(CE),Brazil.
Sarah Suyanne Carvalho
SS
Melgaço
Geraldo Bezerra da
GB
Silva
Amanda Maria Menezes
AM
Dantas
Ana Mirella Arcanjo
AM
Vasconcelos
Verônica Riquet de
VR
Siqueira
Ana Patrícia Freitas
AP
Vieira
Elizabeth de Francesco
Ede F
Daher
D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000368:Aged; D000419:Albuminuria; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D001688:Biological Products / Q000009:adverse effects; D003404:Creatinine / Q000652:urine; D003879:Dermatologic Agents / Q000009:adverse effects*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D000069285:Infliximab; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D003404:Creatinine; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept